Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

Einolf ,Heidi;Hall,Stephen;Williams,Tracy;Patel,Aarti;Gibson ,Christopher;Agrawal,Nancy;Sydor,Jens;

Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

Published on: March 16, 2021

Heidi J. Einolf , Stephen D. Hall, Tracy Williams, Aarti Patel, Christopher Gibson, Nancy G.B. Agrawal, Jens Sydor

BioPharm International, BioPharm International-03-15-2021, Volume 2021 eBook, Issue 1

Pages: 27–30

Basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process are reviewed.

Predictive sciences—built on improved computational capabilities and a deeper understanding of human physiology—are allowing researchers to perform human studies prior to, and sometimes in place of, human clinical trials in order to predict drug outcomes. Representatives of the Translational & ADME Sciences Leadership Group (TALG) in the IQ Consortium review the basic principles of physiologically-based pharmacokinetic (PBPK) modeling and its impact in streamlining the drug development process.

Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.

Article Details

BioPharm International
eBook: Regulatory Sourcebook
March 2021
Pages: 27–30

Citation

When referring to this article, please cite it as H. Einolf, et al., " Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling," BioPharm International Regulatory Sourcebook eBook (March 2021).